Among these, there was a numerical trend indicative of a potential dose–response relationship particularly for pneumonia and sepsis, including septic shock ( table 3 ).
← all excerpts
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).
1
—
—